Serinus Biosciences
Combinations therapy by rational design
About
Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine. Serinus Biosciences is a Y Combinator company (Summer 2022). YC-listed status: Active.
- Website
- serinus.bio
- Location
- New York City, NY, USA; New York, NY, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Serinus Biosciences — AI platform using systems biology to design combination cancer therapies that overcome treatment resistance. · Service
Links
- Y Combinator profileycombinator